Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III photodynamic diagnosis study of SPP-005 in NMIBC during TURBT
jRCT2061210055Phase 3Completed
- Sponsor
- SBI Pharmaceuticals
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of 5-aminolevulinic acid in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by SBI Pharmaceuticals. Primary endpoint: Sensitivity of photodynamic diagnosis under blue light. Started Jan 2022; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2061210055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210055.